Activity of ceftazidime-avibactam against extended-spectrum- and AmpC β-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2849-2857

  Karlowsky, James A ^a   Biedenbach, Douglas J ^a   Kazmierczak, Krystyna M ^a   Stone, Gregory G ^b   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE;

ABDOMINAL INFECTION; AMPC BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; ARTICLE; ASSAY; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENE; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEUS; PROTEUS MIRABILIS; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PROTEUS MIRABILIS;

EID: 84964903457     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02286-15     Document Type: Article

References (28)

1. Bush K. 2013. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 1277:84-90. http://dx.doi.org/10.1111/nyas.12023.
2. Bush K, Fisher JF. 2011. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol 65:455-478. http://dx.doi.org/10.1146/annurev-micro-090110-102911.
3. Jacoby GA. 2009. AmpC β-lactamases. Clin Microbiol Rev 22:161-182. http://dx.doi.org/10.1128/CMR.00036-08.
4. Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663-11668. http://dx.doi.org/10.1073/pnas.1205073109.
5. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL-104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
6. Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA. 2014. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother 58:4290-4297. http://dx.doi.org/10.1128/AAC.02625-14.
7. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58:5704-5713. http://dx.doi.org/10.1128/AAC.03057-14.
8. Forest Pharmaceuticals, Inc. 2014. Avycaz prescribing information. Forest Pharmaceuticals, Inc., Cincinnati, OH.
9. Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Pfizer, Inc. 2010. Tygacil FDA prescribing information. Pfizer, Inc., Collegeville, PA.
12. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, valid from 2015-01-01. European Committee on Antimicrobial Susceptibility Testing, Vaxjo, Sweden. http://www.eucast.org/clinical-breakpoints/.
13. Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF. 2015. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013. Antimicrob Agents Chemother 59:3606-3610. http://dx.doi.org/10.1128/AAC.05186-14.
14. Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S. 2012. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum β-lactamaseproducing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis 74:62-67. http://dx.doi.org/10.1016/j.diagmicrobio.2012.05.024.
15. Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, Hawser SP, Badal RE, Bonomo RA. 2012. Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world. J Clin Microbiol 50:1632-1639. http://dx.doi.org/10.1128/JCM.06115-11.
16. Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ. 2013. Epidemiology and susceptibility of gram-negative appendicitis pathogens: SMART 2008-2010. Surg Infect (Larchmt) 14:203-208. http://dx.doi.org/10.1089/sur.2012.034.
17. Badal RE, Bouchillon SK, Lob SH, Hackel MA, Hawser SP, Hoban DJ. 2013. Etiology, extended-spectrum β-lactamase rates and antimicrobial susceptibility of gram-negative bacilli causing intra-abdominal infections in patients in general pediatric and pediatric intensive care units-global data from the Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010. Pediatr Infect Dis J 32:636-640. http://dx.doi.org/10.1097/INF.0b013e3182886377.
18. Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, Li H, Chen H, He W, Wang Q, Wang H. 2014. In vitro activities of ceftazidimeavibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 58:1774-1778. http://dx.doi.org/10.1128/AAC.02123-13.
19. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58:833-838. http://dx.doi.org/10.1128/AAC.01896-13.
20. Flamm RK, Farrell DJ, Sader HS, Jones RN. 2014. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 69:1589-1598. http://dx.doi.org/10.1093/jac/dku025.
21. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2014. Ceftazidimeavibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80:233-238. http://dx.doi.org/10.1016/j.diagmicrobio.2014.07.005.
22. Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, Badal R, Hoban D, Bonomo RA. 2011. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 66:1992-1997. http://dx.doi.org/10.1093/jac/dkr240.
23. Peirano G, van der Bij AK, Freeman JL, Poirel L, Nordmann P, Costello M, Tchesnokova VL, Pitout JD. 2014. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother 58:3762-3767. http://dx.doi.org/10.1128/AAC.02428-14.
24. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/s40265-013-0013-7.
25. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 58:1684-1692.
26. Keepers TR, Gomez M, Celeri C, Nichols WW, Krause KM. 2014. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 58:5297-5305. http://dx.doi.org/10.1128/AAC.02894-14.
27. Levasseur P, Girard AM, Lavallade L, Miossec C, Pace J, Coleman K. 2014. Efficacy of a ceftazidime-avibactam combination in a murine model of septicaemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum β-lactamases. Antimicrob Agents Chemother 58: 6490-6495. http://dx.doi.org/10.1128/AAC.03579-14.
28. Lahiri SD, Giacobbe RA, Johnstone MR, Alm RA. 2014. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme. J Antimicrob Chemother 69:2942-2946. http://dx.doi.org/10.1093/jac/dku237.